Qualigen Therapeutics (QLGN) Competitors $4.15 -0.01 (-0.24%) As of 11:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock QLGN vs. PYRGF, AKTX, GLTO, IMA, SCYX, PMN, DARE, RNTX, CVKD, and LPTXShould you be buying Qualigen Therapeutics stock or one of its competitors? The main competitors of Qualigen Therapeutics include PyroGenesis Canada (PYRGF), Akari Therapeutics (AKTX), Galecto (GLTO), ImageneBio (IMA), SCYNEXIS (SCYX), Promis Neurosciences (PMN), Dare Bioscience (DARE), Rein Therapeutics (RNTX), Cadrenal Therapeutics (CVKD), and Leap Therapeutics (LPTX). These companies are all part of the "pharmaceutical products" industry. Qualigen Therapeutics vs. Its Competitors PyroGenesis Canada Akari Therapeutics Galecto ImageneBio SCYNEXIS Promis Neurosciences Dare Bioscience Rein Therapeutics Cadrenal Therapeutics Leap Therapeutics Qualigen Therapeutics (NASDAQ:QLGN) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability. Is QLGN or PYRGF more profitable? Qualigen Therapeutics has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. Company Net Margins Return on Equity Return on Assets Qualigen TherapeuticsN/A N/A -202.16% PyroGenesis Canada -115.14%N/A -60.81% Does the media prefer QLGN or PYRGF? In the previous week, Qualigen Therapeutics had 6 more articles in the media than PyroGenesis Canada. MarketBeat recorded 7 mentions for Qualigen Therapeutics and 1 mentions for PyroGenesis Canada. Qualigen Therapeutics' average media sentiment score of 0.78 beat PyroGenesis Canada's score of 0.00 indicating that Qualigen Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qualigen Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PyroGenesis Canada 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher earnings & valuation, QLGN or PYRGF? Qualigen Therapeutics has higher earnings, but lower revenue than PyroGenesis Canada. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQualigen TherapeuticsN/AN/A-$6.26MN/AN/APyroGenesis Canada$9.14M4.01-$21.12M-$0.03-6.50 Do institutionals and insiders have more ownership in QLGN or PYRGF? 3.2% of Qualigen Therapeutics shares are held by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are held by institutional investors. 1.8% of Qualigen Therapeutics shares are held by insiders. Comparatively, 47.7% of PyroGenesis Canada shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more volatility & risk, QLGN or PYRGF? Qualigen Therapeutics has a beta of 0.32, indicating that its share price is 68% less volatile than the S&P 500. Comparatively, PyroGenesis Canada has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500. Do analysts rate QLGN or PYRGF? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryQualigen Therapeutics beats PyroGenesis Canada on 6 of the 10 factors compared between the two stocks. Get Qualigen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QLGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding QLGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QLGN vs. The Competition Export to ExcelMetricQualigen TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.03M$2.61B$6.06B$10.38BDividend YieldN/A57.77%5.73%4.78%P/E RatioN/A23.1786.0626.86Price / SalesN/A615.09582.90180.66Price / CashN/A25.7125.7330.17Price / Book-1.015.3112.686.63Net Income-$6.26M$32.78M$3.31B$276.12M7 Day Performance-17.50%0.79%-0.66%-1.86%1 Month Performance97.62%9.27%8.45%5.63%1 Year Performance-50.57%-0.54%77.27%32.94% Qualigen Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QLGNQualigen TherapeuticsN/A$4.15-0.2%N/A-50.4%$7.03MN/A0.0050Analyst UpgradePYRGFPyroGenesis Canada0.0669 of 5 stars$0.18-2.9%N/A-69.8%$34.04M$9.14M-3.0390News CoverageGap DownAKTXAkari Therapeutics2.7821 of 5 stars$1.04+1.0%$3.30+218.8%-65.6%$33.76MN/A0.009GLTOGalecto0.5709 of 5 stars$25.47+586.4%$10.00-60.7%+74.1%$33.71MN/A-1.9540High Trading VolumeIMAImageneBio3.2982 of 5 stars$8.35-3.0%$35.50+325.1%-61.4%$33.48M$9.16M-1.0970Positive NewsSCYXSCYNEXIS0.6167 of 5 stars$0.78-0.7%N/A-49.7%$32.82M$3.75M-1.9660Gap UpPMNPromis Neurosciences3.4257 of 5 stars$0.56+2.8%$4.33+668.3%-52.0%$30.35MN/A-2.695Analyst DowngradeGap UpDAREDare Bioscience1.7912 of 5 stars$2.22-1.6%$10.00+351.5%-36.7%$29.86M$10K-1.0430News CoveragePositive NewsGap UpRNTXRein Therapeutics3.0854 of 5 stars$1.26+5.9%$10.00+693.7%N/A$29.37MN/A-0.479CVKDCadrenal Therapeutics2.5305 of 5 stars$13.72+1.4%$32.00+133.2%+0.9%$28.13MN/A-1.554LPTXLeap Therapeutics2.5291 of 5 stars$0.67-12.9%$3.38+407.5%-72.4%$27.56MN/A-0.4240Gap Up Related Companies and Tools Related Companies PYRGF Competitors AKTX Competitors GLTO Competitors IMA Competitors SCYX Competitors PMN Competitors DARE Competitors RNTX Competitors CVKD Competitors LPTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QLGN) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Qualigen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Qualigen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
